BIOMAT Database Logo BIOMAT Database Logo

Ciprofloxacin pharmacokinetics in critically ill patients receiving concomitant continuous venovenous hemodialysis. 2015

Matthew S Shotwell, and Phillip N Madonia, and Michael J Connor, and Milen Amde, and Charbel Salem, and Olufemi A Aduroja, and Seth R Bauer, and Joseph J Groszek, and William H Fissell
Vanderbilt University, Nashville, Tennessee.

UI MeSH Term Description Entries
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002939 Ciprofloxacin A broad-spectrum antimicrobial carboxyfluoroquinoline. Bay-09867,Ciprinol,Cipro,Ciprofloxacin Hydrochloride,Ciprofloxacin Hydrochloride Anhydrous,Ciprofloxacin Monohydrochloride Monohydrate,Anhydrous, Ciprofloxacin Hydrochloride,Bay 09867,Bay09867,Hydrochloride Anhydrous, Ciprofloxacin,Hydrochloride, Ciprofloxacin,Monohydrate, Ciprofloxacin Monohydrochloride,Monohydrochloride Monohydrate, Ciprofloxacin
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005260 Female Females
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses

Related Publications

Matthew S Shotwell, and Phillip N Madonia, and Michael J Connor, and Milen Amde, and Charbel Salem, and Olufemi A Aduroja, and Seth R Bauer, and Joseph J Groszek, and William H Fissell
Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis.
January 2011, Critical care medicine,
Matthew S Shotwell, and Phillip N Madonia, and Michael J Connor, and Milen Amde, and Charbel Salem, and Olufemi A Aduroja, and Seth R Bauer, and Joseph J Groszek, and William H Fissell
Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration.
January 2014, Antimicrobial agents and chemotherapy,
Matthew S Shotwell, and Phillip N Madonia, and Michael J Connor, and Milen Amde, and Charbel Salem, and Olufemi A Aduroja, and Seth R Bauer, and Joseph J Groszek, and William H Fissell
Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration.
September 2004, British journal of clinical pharmacology,
Matthew S Shotwell, and Phillip N Madonia, and Michael J Connor, and Milen Amde, and Charbel Salem, and Olufemi A Aduroja, and Seth R Bauer, and Joseph J Groszek, and William H Fissell
Pharmacokinetics of Micafungin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis With High Cutoff Membranes.
June 2019, Therapeutic drug monitoring,
Matthew S Shotwell, and Phillip N Madonia, and Michael J Connor, and Milen Amde, and Charbel Salem, and Olufemi A Aduroja, and Seth R Bauer, and Joseph J Groszek, and William H Fissell
Pharmacokinetics of cefoperazone/sulbactam in critically ill patients receiving continuous venovenous hemofiltration.
July 2016, European journal of clinical pharmacology,
Matthew S Shotwell, and Phillip N Madonia, and Michael J Connor, and Milen Amde, and Charbel Salem, and Olufemi A Aduroja, and Seth R Bauer, and Joseph J Groszek, and William H Fissell
Lacosamide Pharmacokinetics in a Critically Ill Patient Receiving Continuous Venovenous Hemofiltration.
February 2018, Pharmacotherapy,
Matthew S Shotwell, and Phillip N Madonia, and Michael J Connor, and Milen Amde, and Charbel Salem, and Olufemi A Aduroja, and Seth R Bauer, and Joseph J Groszek, and William H Fissell
Ceftaroline Pharmacokinetics in a Critically Ill Adult Receiving Continuous Venovenous Hemodiafiltration.
August 2022, The Annals of pharmacotherapy,
Matthew S Shotwell, and Phillip N Madonia, and Michael J Connor, and Milen Amde, and Charbel Salem, and Olufemi A Aduroja, and Seth R Bauer, and Joseph J Groszek, and William H Fissell
Population pharmacokinetics of polymyxin B in critically ill patients receiving continuous venovenous haemofiltration.
July 2022, International journal of antimicrobial agents,
Matthew S Shotwell, and Phillip N Madonia, and Michael J Connor, and Milen Amde, and Charbel Salem, and Olufemi A Aduroja, and Seth R Bauer, and Joseph J Groszek, and William H Fissell
Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration.
January 2013, Antimicrobial agents and chemotherapy,
Matthew S Shotwell, and Phillip N Madonia, and Michael J Connor, and Milen Amde, and Charbel Salem, and Olufemi A Aduroja, and Seth R Bauer, and Joseph J Groszek, and William H Fissell
Continuous arteriovenous and venovenous hemodialysis in critically ill patients.
January 1991, Contributions to nephrology,
Copied contents to your clipboard!